Nutriband (NASDAQ:NTRB) Announces Quarterly Earnings Results

Posted by Andrew Walz on Sep 6th, 2026

Nutriband (NASDAQ:NTRB – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.07) EPS for the quarter, FiscalAI reports. The business had revenue of $0.44 million during the quarter. Nutriband had a negative net margin of 448.25% and a negative return on equity of 112.64%.

Nutriband Trading Up 6.0%

NASDAQ:NTRB opened at $5.97 on Friday. The company has a market cap of $72.60 million, a P/E ratio of -11.26 and a beta of 2.03. Nutriband has a twelve month low of $2.80 and a twelve month high of $8.63. The company’s 50-day moving average price is $3.47 and its 200-day moving average price is $3.67.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. boosted its position in shares of Nutriband Inc. (NASDAQ:NTRB – Free Report) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the period. Vanguard Group Inc. owned approximately 1.68% of Nutriband worth $1,429,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Nutriband has a consensus rating of “Reduce”.

View Our Latest Stock Analysis on NTRB

About Nutriband

(Get Free Report)

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.